Home Cart Sign in  
Chemical Structure| 1005342-46-0 Chemical Structure| 1005342-46-0

Structure of LCL161
CAS No.: 1005342-46-0

Chemical Structure| 1005342-46-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

LCL161 is an IAP inhibitor that inhibits XIAP in HEK293 cells and cIAP1 in MDA-MB-231 cells with IC50s of 35 and 0.4 nM, respectively.

Synonyms: NVP-LCL161

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Rathje, Oliver H. ; Perryman, Lara ; Payne, Richard J. ; Hamprecht, Dieter W. ;

Abstract: Mixed Lineage Kinase domain-Like pseudokinase (MLKL) is implicated in a broad range of diseases due to its role as the ultimate effector of necroptosis and has therefore emerged as an attractive drug target. Here, we describe the development of PROteolysis TArgeting Chimeras (PROTACs) as a novel approach to knock down MLKL through chem. means. A series of candidate degraders were synthesized from a high-affinity pyrazole carboxamide-based MLKL ligand leading to the identification of a PROTAC mol. that effectively degraded MLKL and completely abrogated cell death in a TSZ model of necroptosis. By leveraging the innate ability of these PROTACs to degrade MLKL in a dose-dependent manner, the quant. relationship between MLKL levels and necroptosis was interrogated. This work demonstrates the feasibility of targeting MLKL using a PROTAC approach and provides a powerful tool to further our understanding of the role of MLKL within the necroptotic pathway.

Alternative Products

Product Details of LCL161

CAS No. :1005342-46-0
Formula : C26H33FN4O3S
M.W : 500.63
SMILES Code : C[C@H](NC)C(N[C@@H](C1CCCCC1)C(N2[C@H](C3=NC(C(C4=CC=C(F)C=C4)=O)=CS3)CCC2)=O)=O
Synonyms :
NVP-LCL161
MDL No. :MFCD23160049
InChI Key :UFPFGVNKHCLJJO-SSKFGXFMSA-N
Pubchem ID :24737642

Safety of LCL161

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • cIAP

In Vitro:

Cell Line
Concentration Treated Time Description References
A549 0–200μM 48 hours To evaluate the cytotoxic effects of LCL161 and paclitaxel, results showed that paclitaxel significantly reduced cell viability, while LCL161 alone had minimal effect. PMC5062899
H460 0–200μM 48 hours To evaluate the cytotoxic effects of LCL161 and paclitaxel, results showed that paclitaxel significantly reduced cell viability, while LCL161 alone had minimal effect. PMC5062899
EMT6 cells 100 nM 2 hours To test the effect of LCL161 on EMT6 cell viability, results showed that LCL161 significantly reduced cell viability. PMC5570934
BMDMs 50 nM, 250 nM, 1000 nM 24 hours To test the effect of LCL161 on IFN-γ and TNF-α expression in BMDMs, results showed that LCL161 increased the expression of these cytokines. PMC5570934
A549 25 μM 24 h To evaluate the effect of LCL161 on A549 cell elongation, invasion and migration, it was found that LCL161 stimulated A549 cell elongation, invasion and migration at non-toxic concentrations. PMC7667862
H1299 10 μM 24 h To evaluate the effect of LCL161 on H1299 cell elongation, invasion and migration, it was found that LCL161 stimulated H1299 cell elongation, invasion and migration at non-toxic concentrations. PMC7667862
μM.1S cells 5 µM 24 hours LCL161 and LBH589 synergistically induced apoptosis in μM.1S cells PMC8679669
U266 cells 5 µM 24 hours LCL161 and LBH589 synergistically induced apoptosis in U266 cells PMC8679669
SW480 cells 10 μM 1 hour LCL161 disrupted the association of BIRC2 with H3 and induced BIRC2 degradation PMC10702411
human macrophages 10 μM 24 hours LCL161 induced BIRC2 degradation and increased IL-6 and RANTES expression PMC10702411

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Nude mice H460 subcutaneous tumor model Intraperitoneal injection 100 mg/d Daily, for 10 months To evaluate the antitumor efficacy of LCL161 and paclitaxel combination, results showed that the combination significantly inhibited tumor growth with minimal toxicity. PMC5062899
mice EMT6 breast tumor model oral 5 mM 1 hour and 18 hours To test the effect of LCL161 combined with VSVΔM51 on EMT6 tumors, results showed that the combination therapy significantly enhanced CD8+T cell-mediated anti-tumor immune responses. PMC5570934
BALB/c nude mice Lung cancer model Intraperitoneal injection 10 mg/kg LCL161 and/or 20 mg/kg paclitaxel Every two days for three weeks To evaluate the inhibitory effect of OTUD7B on LCL161-induced lung cancer cell metastasis in vivo, it was found that OTUD7B inhibited LCL161-induced intrapulmonary metastasis of lung cancer cells. PMC7667862
Mice 5TGM1 murine multiple myeloma model Intraperitoneal injection 50 mg/kg every 72 hours, total of four times Combined LCL161 and LBH589 treatment significantly increased survival in mice PMC8679669
mice oral (PO), intravenous (IV), intraperitoneal (IP) 2 mg/kg Every 2 days for 3 weeks To evaluate the pharmacokinetic properties of 142D6, the results showed that 142D6 is orally bioavailable with an oral bioavailability of 36%. PMC10291551
NSG mice LuCaP 170.3 PDX model Oral 30 mg/kg (PO and IP), 10 mg/kg (IV) single dose, duration of 24 hours To evaluate the therapeutic efficacy of LCL161 in HNF1A+ mCRPC models. Results showed that LCL161 monotherapy significantly inhibited tumor growth in the HNF1A+ LuCaP 170.3 model, while it had minimal effect in the HNF1A- LuCaP 170.2 model. PMC11722106
BALB/c mice 4T1H-2Kb KO tumor model Intravenous injection 100 nM 4 hours LMN significantly inhibited the growth of 4T1H-2Kb KO tumors and prolonged the survival of mice. PMC11252456

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01098838 Advanced Solid Tumors PHASE1 COMPLETED 2025-01-11 UNC/ Lineberger Comprehensive ... More >>Cancer Center Dept. of LinbergerCancerCtr(2), Chapel Hill, North Carolina, 27599-7295, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, 19111-2497, United States|Sarah Cannon Research Institute DeptofSarahCannonRes.Inst. (2), Nashville, Tennessee, 37203, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.00mL

0.40mL

0.20mL

9.99mL

2.00mL

1.00mL

19.97mL

3.99mL

2.00mL

 

Historical Records

Categories